Gilder Gagnon Howe & Co. LLC Has $4.63 Million Stake in Teladoc, Inc. (TDOC)

Gilder Gagnon Howe & Co. LLC increased its position in Teladoc, Inc. (NYSE:TDOC) by 11,741.7% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 133,338 shares of the health services provider’s stock after buying an additional 132,212 shares during the period. Gilder Gagnon Howe & Co. LLC owned about 0.24% of Teladoc worth $4,627,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Parametric Portfolio Associates LLC bought a new stake in shares of Teladoc during the first quarter worth approximately $1,134,000. Eagle Asset Management Inc. bought a new stake in shares of Teladoc during the first quarter worth approximately $32,598,000. Ameriprise Financial Inc. boosted its stake in shares of Teladoc by 125.7% in the first quarter. Ameriprise Financial Inc. now owns 131,493 shares of the health services provider’s stock worth $3,288,000 after buying an additional 73,231 shares during the period. UBS Asset Management Americas Inc. bought a new stake in shares of Teladoc during the first quarter worth approximately $271,000. Finally, Swiss National Bank boosted its stake in shares of Teladoc by 37.5% in the first quarter. Swiss National Bank now owns 56,800 shares of the health services provider’s stock worth $1,420,000 after buying an additional 15,500 shares during the period. 95.88% of the stock is owned by institutional investors and hedge funds.

Teladoc, Inc. (NYSE:TDOC) opened at 31.95 on Thursday. Teladoc, Inc. has a 12-month low of $14.00 and a 12-month high of $36.90. The firm’s 50-day moving average price is $34.10 and its 200 day moving average price is $27.41. The company’s market capitalization is $1.75 billion.

Teladoc (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.02. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The business had revenue of $44.60 million for the quarter, compared to analyst estimates of $44.39 million. During the same quarter in the previous year, the business posted ($0.38) earnings per share. The business’s revenue was up 68.3% on a year-over-year basis. On average, analysts expect that Teladoc, Inc. will post ($1.33) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “[[title]]” was reported by [[site]] and is the property of of [[site]]. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at [[permalink]].

A number of brokerages recently commented on TDOC. Cantor Fitzgerald reaffirmed a “hold” rating and set a $27.00 price objective on shares of Teladoc in a research note on Monday, June 19th. Canaccord Genuity reaffirmed a “buy” rating and set a $42.00 price objective (up from $34.00) on shares of Teladoc in a research note on Tuesday, June 20th. William Blair reaffirmed an “outperform” rating on shares of Teladoc in a research note on Tuesday, June 20th. Chardan Capital lifted their price objective on Teladoc from $30.00 to $41.00 and gave the stock a “buy” rating in a research note on Tuesday, June 20th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $32.00 price objective on shares of Teladoc in a research note on Friday, July 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company’s stock. Teladoc currently has a consensus rating of “Buy” and a consensus target price of $35.55.

In other Teladoc news, insider Adam C. Vandervoort sold 53,806 shares of the stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $30.92, for a total transaction of $1,663,681.52. Following the completion of the sale, the insider now directly owns 33,008 shares in the company, valued at approximately $1,020,607.36. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Mark Hirschhorn sold 100,000 shares of the stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $27.70, for a total value of $2,770,000.00. Following the sale, the vice president now owns 80,887 shares of the company’s stock, valued at $2,240,569.90. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 207,186 shares of company stock valued at $6,122,950. Company insiders own 5.94% of the company’s stock.

About Teladoc

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.